In 2014, Sanofi subsidiary Genzyme and Alnylam agreed to develop and commercialise new RNAi therapeutics for rare genetic diseases. Credit: © Sanofi.

Sanofi has concluded the research and option phase of an RNAi therapeutics partnership in rare genetic diseases forged with biopharmaceutical company Alnylam Pharmaceuticals in 2014.

Under the terms of the deal, Alnylam will develop an undisclosed investigational, rare genetic disease asset through the completion of investigational new disease (IND)-enabling studies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sanofi will be responsible for the product’s further development and commercialisation. If the candidate is approved, Alnylam will be eligible for tiered double-digit royalties on its net sales worldwide.

Furthermore, the partners have agreed to change select terms of their equity agreement to provide Sanofi with access to its lock-up of Alnylam stock holdings.

“Sanofi will be responsible for the product’s further development and commercialisation. Alnylam will be eligible for tiered double-digit royalties on its net sales worldwide.”

Sanofi Research and Development global head John Reed said: “Our alliance with Alnylam has successfully brought one important medicine to patients with ATTR amyloidosis and it also has spawned a molecule that is in pivotal clinical trials for people with haemophilia.

“As we wrap up this phase of our programme with Alnylam, we remain committed to advancing therapies for patients with rare diseases and rare blood disorders.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In January last year, Sanofi and Alnylam restructured their alliance, with Sanofi receiving global development and commercialisation rights to fitusiran, an investigational RNAi therapeutic for haemophilia A and B treatment.

Meanwhile, Alnylam gained global development and commercialisation rights to patisiran and ALN-TTRsc02 (vutrisiran) in ATTR amyloidosis.

Following the closing of the option phase, these material collaboration terms for patisiran, vutrisiran and fitusiran will remain unchanged.